MIM
CTNM

MetLife Investment Management’s Contineum Therapeutics CTNM Stock Holding History

MetLife Investment Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,029
Closed -$103K – 2829
2024
Q4 		$103K Buy
+7,029
New +$111K ﹤0.01% 2611
2024
Q3 		– Sell
-1,926
Closed -$33.9K – 2900
2024
Q2 		$33.9K Buy
+1,926
New +$31K ﹤0.01% 2831

Other funds holding CTNM

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

MetLife Investment Management's CTNM Position: Q1 2025 in Review

MetLife Investment Management sold out of Contineum Therapeutics (CTNM) in Q1 2025, closing a stake of 7,029 shares — an estimated $103K sold.

MetLife Investment Management first reported a position in CTNM in Q2 2024 and held it in 2 quarters. The position peaked at $103K in Q4 2024. 63 funds tracked by Wall St. Rank hold CTNM as of Q1 2025.

  • MetLife Investment Management reported no remaining Contineum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • MetLife Investment Management sold 7,029 Contineum Therapeutics shares in Q1 2025, an estimated $103K.
  • MetLife Investment Management first reported a position in Contineum Therapeutics in Q2 2024 and held it in 2 quarters.
  • MetLife Investment Management's Contineum Therapeutics position peaked at $103K in Q4 2024.
  • 63 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2025.

Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.